10-Q: Achieve Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Achieve Life Sciences reports a net loss of $15.0 million for the first half of 2024, while advancing its cytisinicline program towards potential FDA approval.

Summary

• Achieve Life Sciences is a clinical-stage pharmaceutical company focused on developing cytisinicline for smoking cessation and nicotine addiction.
• The company reported a net loss of $15.0 million for the six months ended June 30, 2024, and an accumulated deficit of $180.7 million.
• As of June 30, 2024, Achieve had cash, cash equivalents, and short-term investments totaling $61.3 million and a positive working capital balance of $48.8 million.
• Net cash used in operating activities for the six months ended June 30, 2024, was $10.2 million.
• The company is progressing with its ORCA-OL open-label trial to gather long-term safety data for cytisinicline, which is expected to support an NDA submission in the first half of 2025.
• Achieve received Breakthrough Therapy designation from the FDA for cytisinicline for nicotine e-cigarette cessation.
• The company has completed Phase 1, Phase 2, and Phase 3 clinical trials for cytisinicline, demonstrating its efficacy in smoking and vaping cessation.
• Achieve is dependent on Sopharma for the manufacture and supply of cytisinicline.
• The company has entered into a new contingent convertible debt agreement for $10.0 million, with potential for an additional $10.0 million based on certain milestones.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the progress in clinical development and the financial challenges. The positive clinical trial results and the Breakthrough Therapy designation are encouraging, but the company's reliance on a single supplier and the lack of current revenue temper the overall sentiment.

Positives

• The company has a strong cash position of $61.3 million.
• The ORCA-OL trial is underway and expected to provide necessary safety data for NDA submission.
• Breakthrough Therapy designation from the FDA could expedite the review process for cytisinicline.
• Completed Phase 3 trials have shown positive results for cytisinicline in smoking cessation.
• The company has secured additional financing through a new debt agreement.

Negatives

• The company has incurred a net loss of $15.0 million for the first half of 2024.
• Achieve has an accumulated deficit of $180.7 million.
• The company is dependent on a single supplier, Sopharma, for cytisinicline.
• There is no guarantee that the FDA will approve cytisinicline without additional studies.
• The company has no current revenue from product sales.

Risks

• Failure to obtain additional financing could hinder the development and commercialization of cytisinicline.
• The company's substantial debt could impair financial flexibility and access to capital.
• There is no guarantee that cytisinicline will be successfully developed and commercialized.
• Reliance on a single supplier for cytisinicline poses a risk to the supply chain.
• The FDA may require additional clinical or non-clinical studies before approving cytisinicline.
• Cytisinicline may cause undesirable side effects that could delay or prevent regulatory approval.
• The company faces substantial competition in the smoking cessation market.
• The company may not be successful in obtaining or maintaining necessary rights to cytisinicline.

Future Outlook

Achieve anticipates submitting an NDA for cytisinicline in the first half of 2025, based on the results of the ORCA-OL trial and previous Phase 3 data. The company believes its existing cash will be sufficient to fund operations into the second half of 2025.

Management Comments

• Management believes cytisinicline represents a unique opportunity to significantly impact global health by addressing the considerable unmet need among millions of smokers and e-cigarettes users.
• Management believes cytisinicline is differentiated from existing smoking cessation treatments given its combination of robust efficacy, minimal frequency of side effects and optional shorter course of therapy.

Industry Context

The document highlights the significant unmet need in the smoking cessation market, with millions of adults in the U.S. using combustible cigarettes and e-cigarettes. Achieve's cytisinicline is positioned as a potential new prescription medicine in this space, competing with existing treatments and addressing the growing concern over nicotine addiction.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies' financial results, but it does mention that Achieve faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• The company's focus on cytisinicline as a novel treatment for nicotine addiction is a key differentiator, as there are currently no FDA-approved therapies specifically for e-cigarette cessation.
• The company's Phase 3 trial results are compared to placebo, but not to other specific smoking cessation products.
• The document notes that cytisinicline is a plant-based alkaloid, which is a different approach than some synthetic drugs in the market.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and regulatory approvals is positive, but the financial losses and reliance on external funding pose risks.
• Employees: The company's growth and development activities may provide opportunities, but the financial challenges could lead to uncertainty.
• Customers: The potential approval of cytisinicline could provide a new treatment option for smoking cessation and nicotine addiction.
• Suppliers: The company's reliance on Sopharma as a single supplier creates a dependency risk.
• Creditors: The company's debt obligations and ability to repay them are a concern.

Next Steps

• Continue enrollment in the ORCA-OL open-label trial.
• Prepare for an NDA submission to the FDA in the first half of 2025.
• Continue to monitor and manage the supply chain for cytisinicline.
• Explore potential strategic collaborations and partnerships.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine addiction, clinical trials, FDA approval, pharmaceutical, ORCA-OL, Breakthrough Therapy, debt financing, Sopharma